Imaging agent - PDFSEARCH.IO - Document Search Engine

Imaging agent
Results: 111

#	Item
71	[removed]Irving Institute CaMPR Phase I Application Progress in molecular imaging: using nanoparticles to image cellular targets Principal Investigator: Diana Martinez, MD Specific Aims The specific aim of this Phase I p Add to Reading List Source URL: irvinginstitute.columbia.edu Language: English - Date: 2012-02-13 14:35:33 Medical imaging Nanomaterials Radiation oncology Positron emission tomography Molecular imaging Imaging agent Single-photon emission computed tomography Nanoparticle Magnetic nanoparticles Medicine Medical physics Neuroimaging
72	[removed]Gadobendate Clinical PREA Add to Reading List Source URL: www.fda.gov Language: English Gadolinium Gadopentetic acid Gadodiamide Magnetic resonance imaging MRI contrast agent Nephrogenic systemic fibrosis Gadobenic acid Chemistry Matter Medicine
73	[removed]Gadobutrol Clinical PREA Add to Reading List Source URL: www.fda.gov Language: English Gadopentetic acid Gadolinium MRI contrast agent Magnetic resonance imaging Gadodiamide Food and Drug Administration Brain tumor Nephrogenic systemic fibrosis Chemistry Medicine Matter
74	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EOVIST® Injection safely and effectively. See full prescribing information for EOVIST Injection. EOVIST (Gadoxetate Add to Reading List Source URL: www.accessdata.fda.gov Language: English - Date: 2013-10-18 16:30:47 Nephrogenic systemic fibrosis Nephrology Gadolinium Lorazepam Magnetic resonance imaging MRI contrast agent Flucytosine Chemistry Matter Organochlorides
75	The recommended dose of Gadavist is 0.1 mL/kg body weight (0.1 mmol/kg), administered as an intravenous bolus injection at a flow rate of approximately 2 mL/second. Flush the intravenous cannula with physiological saline Add to Reading List Source URL: www.accessdata.fda.gov Language: English - Date: 2013-10-18 16:38:58 Gadolinium Nephrogenic systemic fibrosis Magnetic resonance imaging Radiocontrast agent Ketorolac Lorazepam MRI contrast agent Cardiac MRI perfusion Chemistry Matter Gadodiamide
76	Multihance (gadobenate dimeglumine) injection label Add to Reading List Source URL: www.accessdata.fda.gov Language: English - Date: 2010-12-21 13:20:36 Gadodiamide Nephrogenic systemic fibrosis Gadolinium Magnetic resonance imaging Lorazepam MRI contrast agent Cardiac MRI perfusion Chemistry Matter Medicine
77	Ablavar (gadofosveset trisodium) solution label Add to Reading List Source URL: www.accessdata.fda.gov Language: English - Date: 2010-12-21 10:25:06 Nephrogenic systemic fibrosis Nephrology Gadolinium Magnetic resonance imaging MRI contrast agent Gadodiamide Chemistry Matter Medicine
78	OptiMARK™ 0.5 mmol/mL (Gadoversetamide Injection) PRESCRIBING INFORMATION Rx only Mallinckrodt Inc. May 2013 Add to Reading List Source URL: www.accessdata.fda.gov Language: English - Date: 2013-05-23 16:04:28 Medicine MRI contrast agent Nephrogenic systemic fibrosis Gadolinium Magnetic resonance imaging Renal failure Gadoversetamide Chemistry Nephrology Matter
79	Structural spectroscopic analysis of tumour vasculature pre and post contrast agent administration G. S. Almeida 1,2 , I. Wilson 1,2 , L. Farr 3 , and R. J. Maxwell 1,2 1 Northern Institute for Cancer Research, Newcastle Add to Reading List Source URL: www.acuitasmedical.com Language: English - Date: 2013-05-08 12:27:41 Magnetic resonance imaging Spectroscopy Cancer research
80	PDF Document Add to Reading List Source URL: www.ismrm.org Language: English - Date: 2013-03-25 15:35:56 Cardiac magnetic resonance imaging Spin–spin relaxation MRI contrast agent Breast MRI In vivo magnetic resonance spectroscopy Relaxation Centre for Magnetic Resonance Investigations Diffusion MRI Magnetic resonance imaging Medical imaging Medicine

UPDATE